{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:32:54Z","timestamp":1789237974992,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.humpath.2015.12.015","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T02:01:58Z","timestamp":1452132118000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0802-2883","authenticated-orcid":false,"given":"Paul W.","family":"Harms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Hovelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi K.","family":"Cani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela J.","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Fullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleodor","family":"Andea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Tomlins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2015.12.015_bb0005","first-page":"43","article-title":"Eccrine porocarcinoma: a report of 2 cases and review of the literature","volume":"93","author":"Nguyen","year":"2014","journal-title":"Cutis"},{"key":"10.1016\/j.humpath.2015.12.015_bb0010","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00000478-200106000-00002","article-title":"Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases","volume":"25","author":"Robson","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archderm.1963.01590230105015","article-title":"Epidermotropic eccrine carcinoma. A case combining features of eccrine poroma and Paget's dermatosis","volume":"88","author":"Pinkus","year":"1963","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/00000372-200110000-00003","article-title":"P53 protein expression in eccrine poroma and porocarcinoma","volume":"23","author":"Akalin","year":"2001","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0025","first-page":"267","article-title":"Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas","volume":"49","author":"Biernat","year":"1998","journal-title":"Pol J Pathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0560.2000.027001030.x","article-title":"Genetic changes in sweat gland carcinomas","volume":"27","author":"Takata","year":"2000","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00000372-199510000-00005","article-title":"p53 protein and proliferating cell nuclear antigen in eccrine poroma and porocarcinoma. an immunohistochemical study","volume":"17","author":"Tateyama","year":"1995","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0040","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/modpathol.2011.48","article-title":"A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas","volume":"24","author":"Dias-Santagata","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00428-014-1699-y","article-title":"Tumor evolution and progression in multifocal and paired non-invasive\/invasive urothelial carcinoma","volume":"466","author":"Warrick","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2015.12.015_bb0050","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","article-title":"Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy","volume":"75","author":"McDaniel","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2015.12.015_bb0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neo.2015.03.004","article-title":"Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors","volume":"17","author":"Hovelson","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.humpath.2015.12.015_bb0060","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2015.1618","article-title":"Next-generation sequencing of tubal intraepithelial carcinomas","volume":"1","author":"McDaniel","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0065","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature11690","article-title":"Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants","volume":"493","author":"Fu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2015.12.015_bb0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11632","article-title":"An integrated map of genetic variation from 1,092 human genomes","volume":"491","author":"1000 Genomes Project","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2015.12.015_bb0075","author":"Exome Aggregation Consortium"},{"key":"10.1016\/j.humpath.2015.12.015_bb0080","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/1541-7786.MCR-14-0578","article-title":"Next-gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors","volume":"13","author":"Cani","year":"2015","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.humpath.2015.12.015_bb0085","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.humpath.2014.06.003","article-title":"HRAS mutations are frequent in inverted urothelial neoplasms","volume":"45","author":"McDaniel","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0090","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/modpathol.2013.77","article-title":"Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi","volume":"26","author":"Bender","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/jmoldx.2008.070178","article-title":"EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression","volume":"10","author":"Li","year":"2008","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2015.12.015_bb0100","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.humpath.2015.12.015_bb0105","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1158\/0008-5472.CAN-15-0702","article-title":"The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma","volume":"75","author":"Harms","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2015.12.015_bb0110","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.1253735","article-title":"The melanoma revolution: from UV carcinogenesis to a new era in therapeutics","volume":"346","author":"Lo","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.humpath.2015.12.015_bb0115","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational landscape of aggressive cutaneous squamous cell carcinoma","volume":"20","author":"Pickering","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"Suppl 3","key":"10.1016\/j.humpath.2015.12.015_bb0120","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2164-14-S3-S7","article-title":"Assessment of computational methods for predicting the effects of missense mutations in human cancers","volume":"14","author":"Gnad","year":"2013","journal-title":"BMC Genomics"},{"key":"10.1016\/j.humpath.2015.12.015_bb0125","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0002-9440(10)64609-3","article-title":"Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features","volume":"157","author":"Bastian","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.2316","article-title":"Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome","volume":"44","author":"Groesser","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2015.12.015_bb0135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mc.2940040306","article-title":"Ras gene mutation and amplification in human nonmelanoma skin cancers","volume":"4","author":"Pierceall","year":"1991","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.humpath.2015.12.015_bb0140","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.humpath.2014.11.002","article-title":"Activating mutations in the RAS\/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum","volume":"46","author":"Shen","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2015.12.015_bb0145","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1056\/NEJMc1109381","article-title":"HRAS mutation mosaicism causing urothelial cancer and epidermal nevus","volume":"365","author":"Hafner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2015.12.015_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.cmr.0000215035.38436.87","article-title":"BRAF somatic mutations in malignant melanoma and melanocytic naevi","volume":"16","author":"Thomas","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.humpath.2015.12.015_bb0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/aps.2014.129","article-title":"The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer","volume":"36","author":"Guin","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.humpath.2015.12.015_bb0160","article-title":"The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Emicro-MYC driven B-cell lymphoma","author":"Walton","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2015.12.015_bb0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/PPO.0000000000000147","article-title":"Epidermal growth factor receptor\u2013mutant lung cancer: new drugs, new resistance mechanisms, and future treatment options","volume":"21","author":"Piotrowska","year":"2015","journal-title":"Cancer J"},{"key":"10.1016\/j.humpath.2015.12.015_bb0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/BJ20080728","article-title":"Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations","volume":"415","author":"Avizienyte","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.humpath.2015.12.015_bb0175","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-04-1981","article-title":"Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer","volume":"11","author":"Chou","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2015.12.015_bb0180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1476-4598-8-82","article-title":"Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies","volume":"8","author":"Do","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.humpath.2015.12.015_bb0185","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12967-014-0299-6","article-title":"High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma","volume":"12","author":"Ku","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.humpath.2015.12.015_bb0190","author":"ClinVar"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T17:28:04Z","timestamp":1600018084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":38,"alternative-id":["S0046817716000046"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2015.12.015","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2015.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}